stockrow
Monday 9 November 2026
Export RNA’s income statement to Excel — free account
Atrium Therapeutics, Inc.
RNAAtrium Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.8 million, up 72.1% from fiscal 2024.
8.34
0.02
+0.24%
Follow RNA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | 0 | 2 | 7 | 9 | 9 | 10 | 11 | 19 | 28 | +74.6% | 35 | 2 | — | (70.8%) | |
| Gross margin, % | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 0.0 pt | ||||||
| EBT | — | — | (11) | (25) | (44) | (118) | (174) | (212) | (322) | (685) | (57) | +79.9% | ||||||
| EBT margin, % | — | — | (2,959.37) | (1,066.58) | (653.53) | (1,265.38) | (1,886.33) | (2,219.87) | (2,957.71) | (3,650.39) | (203.67) | (691.0) pt | ||||||
| Net income | — | — | — | — | — | — | — | — | — | — | (50) | — | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.64 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash flow | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Capex | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Book value | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.54 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | — | — | — | 17 | — | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.08 | 0.0 | ||||||
| P/B | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.66 | 0.0 | ||||||
| EV/Sales | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (4.33) | 0.0 | ||||||
| EV/FCF | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.09 | 0.0 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | — | — | (58) | — | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | (58) | — | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 85 | 317 | 381 | 571 | 531 | 1,444 | 1,603 | 244 | +63.0% | |||||
| Net debt | — | — | — | (93) | (328) | (406) | (611) | (595) | (1,501) | (1,697) | (264) | +62.3% | ||||||
| Shareholders’ equity | — | — | — | 69 | 306 | 381 | 578 | 501 | (61) | (63) | 215 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | 0.00 | (51.05) | (20.59) | (30.99) | (32.63) | (33.49) | (29.40) | (214.99) | (40.74) | (215.0) pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | 0.00 | 0.00 | 99.98 | 94.00 | 64.08 | 45.67 | 44.04 | 55.42 | 0.00 | +55.4 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Atrium Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PYXS Pyxis Oncology, Inc. | $198.6M | — (loss-making) | — (loss-making) | — | n/m | −5.46% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| TRDA Entrada Therapeutics, Inc. | $191.5M | — (loss-making) | — (loss-making) | −43.93% (below 0%: shrinking) | n/m | −7.05% (below 0%: shrinking) | 100.00% | (4,606.52%) | Compare |
| PRQR ProQR Therapeutics N.V. | $190.5M | — (loss-making) | — (loss-making) | +135.03% (above 0%: growing) | n/m | −1.06% (below 0%: shrinking) | 100.00% | (100.72%) | Compare |
| RNA Atrium Therapeutics, Inc. | $185.8M | — (loss-making) | — (loss-making) | — | n/m | — | 100.00% | (752.93%) | |
| CGEN Compugen Ltd. | $185.7M | 5.2× | — (loss-making) | +107.00% (above 0%: growing) | n/m | −155.42% (below 0%: shrinking) | (3.54%) | (339.62%) | Compare |
| KROS Keros Therapeutics, Inc. | $183.7M | — (loss-making) | — (loss-making) | +120.22% (above 0%: growing) | n/m | +6.87% (above 0%: growing) | 100.00% | 32.04% | Compare |
| BCYC Bicycle Therapeutics PLC Sponsored ADR | $182.5M | — (loss-making) | — (loss-making) | +190.24% (above 0%: growing) | n/m | +43.48% (above 0%: growing) | 100.00% | (39.57%) | Compare |
| ACOG Alpha Cognition Inc. | $180.5M | — (loss-making) | — (loss-making) | +267.56% (above 0%: growing) | n/m | −109.25% (below 0%: shrinking) | 94.80% | (127.29%) | Compare |
| UPB Upstream Bio, Inc. | $176.9M | — (loss-making) | — (loss-making) | −17.50% (below 0%: shrinking) | n/m | +9.33% (above 0%: growing) | 100.00% | (5,480.98%) | Compare |
| Median of peers | $184.7M | — | — | +120.22% | — | −3.26% | 100.00% | (114.00%) |